- Home
- CPBI vs TIL Comparison
CPBI vs TIL Comparison
Compare CPBI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | TIL |
|---|---|---|
| Founded | 2023 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 74.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CPBI | TIL |
|---|---|---|
| Price | $17.75 | $8.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 3.8K | ★ 24.7K |
| Earning Date | 06-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.52 | $5.67 |
| 52 Week High | $17.89 | $42.75 |
Technical Indicators
Market Signals| Indicator | CPBI | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 58.42 |
| Support Level | $16.88 | $7.88 |
| Resistance Level | $17.88 | $9.05 |
| Average True Range (ATR) | 0.27 | 0.51 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 87.67 | 92.62 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.